Healthcare
Alpha Tau Medical Ltd.(DRTS)
Live Price
Offline$9.78
+1.77% today
1Y Change
+235.00%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $650.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -17.8%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpha Tau Medical Ltd. (DRTS) is a Healthcare stock with a market cap of $650.00M and listed on NASDAQ. The stock last traded around $9.78 and up 235.0% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -17.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -17.8%, free cash flow -48.7% with operating margin 0.0% and ROIC 17.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DRTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -17.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.6% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | +6.5% | +3.4% | -6.8% |
2026 Mar 9, 2026 | -7.7% | +1.9% | +8.0% | +6.4% |
2025 Nov 20, 2025 | -16.7% | +10.1% | +14.4% | +46.1% |
Benchmark Edge
DRTS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DRTS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DRTS Max Drawdown
-23.87%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DRTS and SPY.
Company Overview
Alpha Tau Medical Ltd.
NASDAQ Capital Market
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
- Leadership
- Uzi Sofer
- IPO Date
- Mar 8, 2021
- Employees
- 125
- Street Address
- 5 Kiryat Hamada Street
- Mailing
- Jerusalem, 9777605
- Region
- Jerusalem, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 577 4115
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 8.2
Growth
- Revenue
- 0.0%
- EPS
- -17.8%
- Free Cash Flow
- -48.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -57.3%
- ROIC
- 17.6%
Balance Sheet
- Debt/Equity
- 0.18
- Current Ratio
- 7.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.